Literature DB >> 3979268

Comment on mitoxantrone.

G DuKart, M J Iatropoulos, A Yacobi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3979268     DOI: 10.1177/106002808501900317

Source DB:  PubMed          Journal:  Drug Intell Clin Pharm        ISSN: 0012-6578


× No keyword cloud information.
  6 in total

1.  [Mitoxantrone-induced acute left heart failure after intrapleural administration].

Authors:  H Kahles; H J Bastian; O Schiffmann; M Geck; F R Helmke; N Golz
Journal:  Herz       Date:  1997-08       Impact factor: 1.443

Review 2.  Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  D Faulds; J A Balfour; P Chrisp; H D Langtry
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

3.  Heterogeneity of in vitro chemosensitivity in perioperative breast cancer cells to mitoxantrone versus doxorubicin evaluated by a microplate ATP bioluminescence assay.

Authors:  C M Kurbacher; I A Cree; U Brenne; H W Bruckner; J A Kurbacher; P Mallmann; P E Andreotti; D Krebs
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

4.  Mitoxantrone in combination with prednimustine in treatment of unfavorable non-Hodgkin lymphoma.

Authors:  K E Landys
Journal:  Invest New Drugs       Date:  1988-06       Impact factor: 3.850

5.  Phase I trial of mitoxantrone and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced solid malignancies.

Authors:  J H Schiller; B Storer; R Arzoomanian; K Tutsch; D Alberti; D Spriggs
Journal:  Invest New Drugs       Date:  1993-11       Impact factor: 3.850

6.  Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice.

Authors:  K M Rentsch; D H Horber; R A Schwendener; H Wunderli-Allenspach; E Hänseler
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.